ArticleAntimicrobial agents and chemotherapy1998
Rationale for and efficacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection.
Article in Antimicrobial agents and chemotherapy, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 57 citations in OpenAlex.
- Liposome-Encapsulated Antibiotics for the Therapy of Mycobacterial Infections.Antibiotics (Basel, Switzerland) · 2025Review
- Targeting Intracellular Mycobacteria Using Nanosized Niosomes Loaded with Antibacterial Agents.Nanomaterials (Basel, Switzerland) · 2021Article
- Polyurethane-functionalized starch nanocrystals as anti-tuberculosis drug carrier.Scientific reports · 2021Article
- Nanomedicines as Drug Delivery Carriers of Anti-Tubercular Drugs: From Pathogenesis to Infection Control.Current drug delivery · 2019Review
- Amikacin: Uses, Resistance, and Prospects for Inhibition.Molecules (Basel, Switzerland) · 2017Review
- Nanotechnology-Based Approach in Tuberculosis Treatment.Tuberculosis research and treatment · 2017Review
- Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases.Advanced drug delivery reviews · 2013Review
- Targeted delivery of amikacin into granuloma.American journal of respiratory and critical care medicine · 2010Article
- Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection.Antimicrobial agents and chemotherapy · 2002Article
- Gamma interferon is essential for clearing Mycobacterium genavense infection.Infection and immunity · 2000Article
- Efficacy of microencapsulated rifampin in Mycobacterium tuberculosis-infected mice.Antimicrobial agents and chemotherapy · 1999Article
- Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages.Antimicrobial agents and chemotherapy · 1998Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The potential of liposome-encapsulated antibiotics for prolonging drug application intervals was investigated by using a murine model of chronic lethal Mycobacterium avium infection. Liposomal encapsulation of amikacin, but not of ciprofloxacin, resulted in high and sustained drug levels in infected tissues, exceeding the minimal inhibitory concentration for M. avium for at least 28 days. As a consequence, once-weekly and even once-monthly treatments with liposomal amikacin significantly reduced bacterial replication in infected tissues and extended the survival time of infected mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.